HealthTech Realignment: Why M&A Has Eclipsed the IPO and the Strategic Playbook for Founders

Nelson Advisors
5 hours ago
15 min read

Historically, the healthcare venture capital ecosystem celebrated a massive public market milestone: Initial Public Offerings (IPOs) accounted for an astonishing 94% of the total exit value in the sector. Today, the market faces a complete structural inversion. In the first half of 2025, mergers and acquisitions (M&A) accounted for over 94% of all digital health exits globally, establishing an unassailable dominance by volume and relegating the IPO to a historical mirage for all but a select tier of market leaders.

Of the 113 global digital health exits recorded in the first half of 2025, 107 were executed through M&A transactions, whereas a mere 6 were achieved via public listings. This profound shift marks a permanent structural transition from a phase of speculative, venture-backed exuberance to one of pragmatic, highly disciplined growth.

Metric	Historical Paradigm (2019)	Contemporary Paradigm (2025)	Structural Inversion Mechanism
Dominant Exit Vehicle	Initial Public Offering (IPO)	Mergers and Acquisitions (M&A)	Shift from speculative capital-seeking to strategic consolidation.
94% Threshold Driver	94% of total exit value driven by IPOs	94.7% of all exits by volume driven by M&A	Extreme public market volatility and severe multiple contraction.
Primary Investor Focus	Multi-year cash burn for speculative market share	Capital efficiency and immediate return on investment	Tightening of venture capital liquidity and rising interest rates.
Default Startup Terminal State	Public listing at high revenue multiples	Private strategic trade sale or sponsor-backed roll-up	High compliance costs, public undervaluations, and vendor stack consolidation.

The Shift in Liquidity: Analysing the $13.9 Billion Exit Reality

The absolute dominance of M&A is underscored by the scale of capital redeployment. Globally, digital health exits reached $13.9 Billion in 2025, driven by an accelerating venture capital liquidity crunch and systemic consolidation. This liquidity crunch is characterised by deep negative net cash flows for venture capital firms, which reached a deficit of $32.6 Billion in 2024, forcing limited partners to demand immediate, tangible cash returns.

As global digital health funding fell from its speculative peak of $29.1 Billion in 2021 to $12.6 Billion in 2023, the capital required to sustain late-stage, unprofitable companies evaporated. Startups that previously relied on consecutive venture rounds to fund high burn rates have been forced to pursue M&A as a survival mechanism.

This funding drought has dramatically altered early-stage dynamics. The Series A fundraising process has increasingly evolved into an M&A exit route rather than a bridge to further growth. Venture-to-venture acquisitions, where venture-backed consolidators use fresh capital to acquire venture-backed peers—now account for 27% of all M&A activity.

This roll-up strategy allows early-stage companies to realise value and secure operational shelter without bearing the risk of a prolonged, capital-intensive independent runway. For the middle 70% of venture capital portfolios, which lack a viable pathway to an independent public listing, strategic trade sales and sponsor-backed acquisitions represent the only realistic route to liquidity.

Exit Metric	2020 Peak	2024 Transition	2025 Realised Value	Market Trajectory
Global Digital Health Exit Value	N/A	N/A	$13.9 Billion	Highly concentrated around scaled platform buyouts.
Global Digital Health Exits (H1)	N/A	N/A	113 Exits	Highly consolidated, selective market.
H1 M&A Transactions	N/A	5% YoY Increase	107 Exits	Remains the primary liquidity engine for venture portfolios.
H1 IPO Listings	19% of exits	3% of exits	6 Exits	Restricted to mature, free-cash-flow-positive leaders.
PE Buyout Deal Value	N/A	N/A	EUR 29.6 Billion (YTD)	276% year-over-year surge in financial sponsor activity.
Total European M&A Deal Value	N/A	N/A	EUR 31.8 Billion (H1)	87% value surge despite an 8% drop in overall deal count.
US Private Placement Rebound	N/A	N/A	$5.8 Billion (Q2)	Highest aggregate private capital placement in three years.

Macroeconomic and Structural Drivers of M&A Dominance

The realignment of the exit environment around private transactions is propelled by a combination of technological, strategic, and financial catalysts that favour private consolidation over public exposure.

Large Medtech and Biopharma Pressures

The traditional buyers of healthcare innovation are facing structural business model challenges. Big Pharma continues to experience stagnating returns on internal research and development, driven by opaque tracking metrics and rising execution costs. To optimise research budgets, biopharma giants are turning to advanced, specialised software providers like Alchemy to streamline pipelines and improve R&D efficiency.

Furthermore, a sweeping wave of expiring patents has stripped pharmaceutical companies of market share to generic alternatives, forcing them to find cost-savings through digital pipeline optimisation. Large medtech strategics, armed with significant capital, have shifted their focus from defensive cost-cutting to growth-oriented acquisitions. These giants are actively acquiring smaller innovators with advanced data sets, proprietary algorithms, and established clinical relationships.

Systemic Operational Bottlenecks

The broader healthcare ecosystem is operating under severe stress. Extreme physician overload and clinical burnout have forced health systems to seek scalable digital tools that can automate administrative workflows, clinical scheduling, and billing compliance. This need is compounded by patients becoming highly informed and taking a proactive role in their care, frequently self-diagnosing via resources like WebMD. This new breed of patient demands seamless digital integration and continuous engagement.

Because early-stage startups face long development cycles, complex multi-stakeholder misalignment and high implementation costs, they are often unable to scale independently. Consequently, they look to be acquired by larger healthcare institutions and pharma conglomerates with the deep pockets and distribution networks required to navigate these long cycles.

Strategic Portfolio Optimisation and Portfolio Gaps

Industry giants like UnitedHealth, Amazon, and major biopharma firms are aggressively acquiring digital health companies to fill portfolio gaps in high-growth segments like telehealth, remote patient monitoring (RPM), and AI-driven diagnostics. Strategic buyers seek immediate synergies, such as integrating digital therapeutics or behavioral tools into their existing enterprise care platforms. For instance, Biogen acquired Human Immunology Biosciences, and Johnson & Johnson acquired Intra-Cellular Therapies to counter upcoming patent cliffs and expand their specialty portfolios.

However, strategic buyers must navigate a highly complex regulatory landscape. The U.S. Department of Justice (DOJ) blocked UnitedHealth's proposed acquisition of Amedisys, demonstrating that antitrust hurdles remain a critical risk for large-scale consolidations, even as declining interest rates ease the financing of private deals.

The Private Equity Influx and Buy-and-Build Playbooks

With immense levels of dry powder, private equity (PE) firms are driving a massive consolidation of the healthtech landscape. Globally, healthcare private equity delivered a record performance in 2025, with disclosed deal value exceeding $191 Billion and surpassing the previous speculative high in 2021. Total exit value for healthcare PE jumped to $156 Billion in 2025, up from $54 Billion in 2024, with more than 40 deals exceeding $1 Billion in value.

In Europe, H1 2025 healthcare M&A deal value grew by 87% to EUR 31.8 Billion, even as the total deal count fell by 8%, highlighting a sharp concentration in "mega-mergers". European PE buyout deal value surged 276% to EUR 29.6 Billion.

PE sponsors are deploying buy-and-build strategies, acquiring robust clinical platforms and integrating smaller, specialized point solutions as bolt-ons to achieve operational leverage. Examples include KKR taking a 50% stake in Cotiviti, CD&R and TowerBrook's acquisition of R1 RCM, and Madison Dearborn's buyout of NextGen.

Aaron DeGagne, a senior analyst for healthcare at PitchBook, notes that large public firms are continuously outpacing IPO activity by acquiring private medtech and digital health targets that have moved past outdated, inflated valuations.Alex Wakefield, Chief Revenue Officer of AcuityMD, similarly emphasises that major device manufacturers are aggressively targeting smaller innovators to expand their clinical footprint.

Acquirer / Sponsor	Target Company / Asset	Transaction Value	Strategic Rationale	End-Market Segment
Merck	Verona Pharma	EUR 9.5 Billion	Patent cliff mitigation and pipeline optimisation.	BioPharma / Therapeutics.
Amgen	Horizon Therapeutics	$27.8 Billion	Portfolio expansion in specialty therapeutics.	BioPharma / Immunology.
Siemens	Dotmatics	$5.0 Billion	Expansion of clinical R&D software infrastructure.	Clinical IT / Infrastructure.
ELMO Software	Rotageek	£8.6 Million	PE-backed exit generating a 1.5x money multiple.	Workforce Management.
Patchwork Health	L2P Enterprise	Undisclosed	Integration of appraisal software with active clinical rotas.	Clinical WFM / Suite.
Lantum	Doctors Rostering System	Undisclosed	Modernization of resident doctor pay and compliance.	Clinical WFM / Compliance.
Dexcom	Nutrisense	Undisclosed	Convergence of biosensing, AI diagnostics, and coaching.	Biosensing / Metabolic Health.
Universal Health Services	Talkspace	Undisclosed	Structural convergence in behavioral healthcare.	Telehealth / Behavioral Care.

Deconstructing the IPO Mirage: Case Studies in Market Correction

The collapse of the digital health IPO market is a direct result of a fundamental misalignment between public market expectations and the operational realities of early-stage healthtech companies. During the 2020–2022 digital health boom, cheap capital and telehealth hype allowed companies to go public via SPACs at highly inflated valuations, despite having unproven revenue models and high cash burn rates.

Pear Therapeutics: The Trailblazer Tax

Pear Therapeutics went public through a SPAC but failed to survive the transition due to a severe mismatch between its cash burn and commercial adoption. Pear was a pioneer in prescription digital therapeutics (PDTs), designing software-driven interventions like reSET and reSET-O for substance use disorders, and Somryst for chronic insomnia. Despite presenting real-world evidence at ISPOR Europe 2022 showing per-patient healthcare cost reductions of $8,202 over 24 months, Pear was unable to secure broad commercial insurance coverage.

The company's revenue model relied on state Medicaid programs, which provided insufficient reimbursement rates. Pear lacked the traditional commercial sales muscle of pharmaceutical companies to win over wary providers and payers.Facing a massive operating loss of $123.4 Million on just $12.7 Million in revenue in 2022, Pear laid off 9% of its workforce in July 2022 to save $28 Million.

As its cash reserves dwindled, the company withdrew its financial forecasts, attempted to sell up to $300 Million in stock, and ultimately filed for Chapter 11 bankruptcy in April 2023, liquidating its assets and laying off over 90% of its remaining staff.

Babylon Health and Akili Interactive: Structural Failures

Babylon Health reached a peak valuation of over $2 Billion before going public via a SPAC. The company scaled rapidly but struggled with unsustainable risk-sharing primary care contracts, high customer acquisition costs, and an unproven virtual-first revenue model. In September 2023, Babylon went bankrupt and its UK operations were sold for parts.

Similarly, Akili Interactive was forced to pivot away from its prescription digital therapeutics model after generating just $114,000 in revenue against $15.3 Million in expenses in Q2 2023, illustrating the commercial failure of treating software products like high-priced pharmaceuticals without the backing of established distribution networks.

The 2025 Rational IPO Comeback

While the SPAC-era listings collapsed, 2025 saw a highly selective IPO comeback. Five digital health companies went public: Hinge Health, Omada Health, HeartFlow, Carlsmed, and Profusa. Unlike their predecessors, these companies possessed mature financial structures, clear paths to profitability, and extensive clinical validation.

Hinge Health entered the public market already free-cash-flow positive, boasting a 98% client retention rate and a technology platform that automated 95% of clinician hours for its physical therapy programs. Omada Health crossed 1 million members in Q1 2026, reporting $78 Million in revenue (up 42% year-over-year) and a GAAP gross margin expansion to 62%.

HeartFlow leveraged over 3,000 peer-reviewed papers and secured direct reimbursement from Medicare and private payers for its AI-powered diagnostic platform, creating a highly defensible revenue stream.

These successful listings established that public markets now demand rigorous proof of scale, high gross margins, and clinical validation, making IPOs an unrealistic target for the vast majority of startups and leaving M&A as the default exit pathway.

Company / Asset	Listing Mechanism	Peak Market Value	Primary Financial Failure / Success Driver	Clinical & Reimbursement Foundation
Pear Therapeutics	SPAC	Liquidation	High R&D burn; premature public exposure; lack of pharmaceutical sales muscle.	Insufficient Medicaid coverage; failed to secure commercial payer adoption.
Babylon Health	SPAC	Bankrupt / Sold for parts	High cash burn on unproven risk-sharing primary care models.	Failed to prove clinical or administrative cost-savings to commercial health systems.
Akili Interactive	SPAC	Pivot to Consumer Model	Unsustainable R&D and clinical trial costs; generated just $114K revenue in Q2 2023.	Failed prescription-only model; shifted to non-prescription distribution.
Hinge Health	Traditional IPO	Trading above IPO price	Profitable on a free cash flow basis; high operating margins; 98% client retention.	Virtual musculoskeletal care covered by major employers and health plans.
Omada Health	Traditional IPO	Revenue $78M in Q1 2026 (up 42% YoY)	Reassurance of financial discipline; GAAP gross margin expanded to 62%.	Chronic care platform backed by 29 peer-reviewed clinical studies.
HeartFlow	Traditional IPO	Trading above IPO price	defensible business built around high-growth coronary diagnostics.	AI-powered diagnostic platform supported by 3,000 peer-reviewed papers.

Pre-M&A Playbook for Founders: Channel Partnerships, Cloud Marketplaces and Interoperability

In an environment where M&A represents the default exit, founders must shape their business around the key metrics strategic and financial acquirers care about. Deploying a channel partnership is a highly effective pre-M&A strategy, as a successful channel motion decreases the average sales cycle by 25%, whereas relying solely on direct sales increases it by 10%.

Consequently, 27% of founders launch channel partnerships specifically to reduce customer acquisition costs (CAC).

Commercial Timeline Alignment

Startups execute channel strategies at different stages of maturity. Ciitizen engaged early with patient advocacy groups as marketing and lead-generation channels before its product was fully mature to shape development. Cedar deferred its channel motion, waiting until its fourth year to sign its first major contract to ensure its direct-sales playbook was repeatable first. Ginger established a highly structured partnership with navigation platform Accolade to rapidly scale its mental health services.

Exploiting Cloud Marketplaces

Cloud marketplaces operated by hyperscalers (AWS, Microsoft Azure, Google Cloud Platform) allow healthcare organisations to procure software using pre-allocated cloud spend, bypassing standard procurement friction. Founders must align marketplace selection with their primary buyer persona.

Infrastructure, cybersecurity, and clinical data platforms should prioritize the AWS marketplace, leveraging its strong relationships with hospital CIOs and CISOs. Application software targeting administrative, HR, and financial operations should prioritise Microsoft Azure, leveraging its deep relationships with health system CFOs and revenue-cycle executives.

Navigating Regional and Regulatory Variations

The U.S. market prioritises commercial speed, rapid data integration, and the creation of "algorithmic moats" to capture high-value chronic care markets. Conversely, the European market is highly fragmented, requiring a localised approach to navigate country-specific reimbursement systems (such as the German DiGA framework).

European private equity sponsors rely heavily on buy-and-build strategies, rolling up fragmented medical device manufacturers and Contract Development and Manufacturing Organisations (CDMOs). Startups operating in Europe must ensure strict compliance with GDPR and the European Union Medical Device Regulation (EU MDR).

Furthermore, founders must monitor heightened antitrust scrutiny of below-threshold transactions, illustrated by the French Competition Authority's November 2025 ruling and EUR 4,665,000 fine against Doctolib for abuse of dominance.

Technical Audits and EHR Interoperability

Corporate acquirers conduct thorough technical audits of a target's product architecture before committing to an acquisition. Startups must evaluated their product against key standards :

Data Privacy: Compliance with US HIPAA and European GDPR, historical data breach logs, and user consent records.
Information Security: Compliance with SOC 2, ISO 27001, and PCI DSS.
Medical Device Regulation: Alignment with US FDA premarket notifications and European MDR post-market surveillance.
EHR Integration: Integration with major electronic health record (EHR) systems like Epic, Cerner, and Allscripts. Startups should build on REST-based interoperability standards, specifically Fast Healthcare Interoperability Resources (FHIR) and HL7 connectivity protocols.

To preserve corporate optionality during partnerships, founders should limit legal exclusivity and Right of First Refusal (ROFR) clauses to 30 to 90 days, tie them to clear performance milestones, and include exit clauses if sales targets are missed.

Partnership Model	Functional Mechanism	Strategic Advantage	Operational Risk
Marketing Partners	Top-of-funnel lead generation and referral of qualified prospects.	Validates initial market demand within the partner's client base.	High dependence on the partner's brand awareness; risk of low lead conversion.
Co-Sale Partners	Direct collaboration between the partner's and target's sales forces.	Builds operational rapport and tests cultural and technical alignment.	The "enablement gap"; requires full-time staff to train partner representatives.
Contracting Partners	Utilizes the partner's existing enterprise contracting vehicles.	Eases procurement and billing; bypasses hospital purchasing friction.	Potential "product drift" where the partner's preferences alter the roadmap.
Cloud Marketplaces(AWS/Azure)	Procurement through pre-allocated hyperscaler cloud spend.	Accesses large budgets; fast procurement with CIOs and CFOs.	Requires dedicated staff to manage complex billing and custom CRM workflows.

Capital Structure and the Valuation Stack: Protecting the Cap Table

In an exit environment where valuations have normalised from previous highs, the structural terms within a startup's capitalisation table heavily influence payout distributions. Liquidation preferences serve as a primary downside protection mechanism for investors, ensuring they recoup their capital before founders and employees receive any proceeds.

The Valuation Stack and Boardroom Friction

A liquidation preference dictates how proceeds from a sale are distributed between preferred stock (held by venture capitalists) and common stock (held by founders and employees). In 2025-2026, many startups are exiting below their peak valuations from 2021, creating significant tension among investors.

Because different preferred share classes sit in a specific liquidation stack, often stacked in reverse order (Series D, then C, then B, then A)—late-stage investors are positioned to take most of the proceeds in modest exits.

During M&A negotiations, each preferred class may vote differently depending on their place in the stack. For example, if Series D investors are guaranteed a 1x return but the exit price is just above their investment amount, they have the leverage to block earlier-stage investors from receiving any payout, creating severe boardroom friction.

Liquidation Preference Structures

The economic impact of liquidation preferences depends on the specific structure negotiated in the term sheet :

1x Non-Participating Preferred: The standard, founder-friendly structure. The investor receives either their initial investment back or their pro-rata share of the exit, whichever is greater, but not both.
Participating Preferred ("Double-Dipping"): This structure allows investors to claw back their initial investment first, and also share in the remaining proceeds like everyone else according to their ownership percentage, significantly diluting the return for common shareholders.
Multiple Liquidation Preferences (2x or 3x): Requires the startup to return double or triple the investor's original capital before any other shareholders are paid, often used in late-stage, high-risk, or distressed rounds.
Capped Participation: Offers participation, but caps total investor returns at a multiple of their original investment (typically 2x to 3x) to prevent disproportionate investor returns in large exits.

Exit Payout Simulation

To understand the economic impact of these terms, consider a startup that raised a €2 million Seed round (1x non-participating preferred) and a €10 million Series A round (20% ownership) on a total of €12 million raised, later exiting at €20 million.

Under a standard 1x Non-Participating structure, the Series A investor would convert to common stock and take 20% of the €20 million exit (€4 million), leaving €16 million to be shared among the Seed investor and common shareholders.

However, if the Series A investor negotiated a 1x Participating Preferred structure, the Series A investor would claim their €10 million preference first. They would then take 20% of the remaining €10 million (€2 million), totaling €12 million.

This leaves only €8 million to be shared among the Seed investor and the founders/employees, significantly reducing the common shareholders' expected payout despite the exit being nearly double the total capital raised.

Liquidation Preference Structure	Series A Investor Payout	Seed Investor Payout	Founders & Employees Payout	Common Shareholder Dilution
1x Non-Participating	€4.0 Million	€2.0 Million	€14.0 Million	Standard; founder-friendly downside protection.
1x Participating	€12.0 Million	€1.6 Million	€6.4 Million	Severe; investor "double-dips" and claims 60% of the exit.
2x Non-Participating	€20.0 Million	€0.0 Million	€0.0 Million	Extreme; investor claims the entire exit; all other shareholders wiped out.
1x Participating (Capped at 1.5x)	€12.0 Million	€1.6 Million	€6.4 Million	Partial protection; cap is not reached in this scenario.

Strategic Actions for Founders: Building for Trade Sales

To successfully position their companies for acquisition in this M&A-dominated environment, founders and investors must evaluate their business models against six key strategic questions :

1. Is the business model Scalable?

Founders must demonstrate exactly how the business will grow in the next 2 to 5 years. This requires a clear plan showing whether growth will be driven by direct sales, channel partners, or public procurement tenders.

2. Is growth Sustainable?

Acquirers look for a clear path to profitability rather than unprofitable growth. Startups must document the number of enterprise deals required to reach breakeven and prove that their unit economics are improving over time.

Founders should measure their performance against the SaaS "Rule of 40," which states that a company's year-over-year revenue growth rate plus its EBITDA margin should equal or exceed 40%.

In highly disciplined market conditions, a healthtech firm growing at a sustainable rate of 25% with a 15% EBITDA margin presents a highly attractive, de-risked target for a strategic consolidator or a private equity platform.

Outstanding public performers like iRhythm (+92% YTD), Doximity (+37%), and Sectra (+30%) demonstrate that investors heavily favour scalable, mission-critical platforms that balance growth with margin discipline.

3. Is the value proposition Defendable?

Startups must define their competitive moat. Acquirers seek companies with proprietary clinical data assets, established distribution channels, unique product integrations, regulatory clearances, or long-term strategic partnerships.

4. Are there Multiple Use Cases?

Founders should provide evidence of at least 2 to 5 different use cases for their products or services, supported by concrete clinical and operational case studies that prove a clear return on investment (ROI) for health systems.

5. Can the product expand into Multiple Geographies?

Acquirers value products that are not restricted to a single country's healthcare system. Technology architectures must be fully interoperable with multiple electronic health records (EHRs) and clinical IT systems to facilitate rapid international expansion.

6. Can the company diversify into Multiple Industries?

Founders should design their products to be flexible enough to sell outside of traditional healthcare providers, expanding their target addressable market to commercial insurers, private employers, and biopharma companies.

By answering these questions early in their development, healthtech founders can transition their companies from speculative venture targets into highly attractive, de-risked acquisition opportunities, ensuring successful exits and generating essential liquidity for the venture capital ecosystem.

Nelson Advisors > European MedTech and HealthTech Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech